Vβ17 T cell receptor peptide vaccination in rheumatoid arthritis: Results of phase I dose escalation study

Journal of Rheumatology

Volumn 23, Issue 8, 1996, Pages 1353-1362

  Moreland, Larry W ^a,c,g   Heck Jr , Louis W ^a   Koopman, William J ^a   Anthony Saway, P ^d   Adamson, Thomas C ^e   Fronek, Zdenka ^f   O'Connor, Richard D ^e   Morgan, Elizabeth E ^b   Diveley, Jocelyn P ^b   Richieri, Steven P ^b   Carlo, Dennis J ^b   Brostoff, Steven W ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Orchestra Therapeutics Inc   (United States)

^c Arthr Clinical Intervention Program   (United States)

^d Rheumatology Associates Inc   (United Kingdom)

^e Sharp Rees Stealy Medical Group   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Division of Clinical Immunology   (United States)

Author keywords

Rheumatoid arthritis; T cell receptors; Treatment; Vaccination

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; DICLOFENAC; FLURBIPROFEN; GOLD SALT; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; METHOTREXATE; NABUMETONE; NAPROXEN; PARACETAMOL; PIROXICAM; PREDNISONE; SALAZOSULFAPYRIDINE; T LYMPHOCYTE RECEPTOR; VACCINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AMINO ACID SEQUENCE; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INJECTIONS, INTRAMUSCULAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; VACCINATION; VACCINES, SYNTHETIC;

EID: 9344245755     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Harris ED: Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Koopman WJ, Gay S: Do nonimmunologically mediated pathways play a role in the pathogenesis of rheumatoid arthritis? Rheum Dis Clin North Am 1993;19:107-22.
3. Nepom GT, Erlich H: MHC class-II molecules and autoimmunity. Annu Rev Immunol 1991;9:493-525.
4. Winchester R: The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994;56:389-466.
5. Zagon G, Turnang JR, Li Y, Friedman SM, Crow MK: Increased frequency of Vß17-positive T cells in patients with rheumatoid arthritis. Arthritis Rheum 1994;37:1431-40.
6. Goronzy JJ, Bartz-Bazzanella P, Hu W, Jendro MC, Walser-Kuntz DR, Weyand CM: Dominant clonotypes in the repertoire of peripheral CD4+ T cells in rheumatoid arthritis. J Clin Invest 1994;94:2068-76.
7. Paliard X, West S, Lafferty J, et al: Evidence for the effects of a superantigen in rheumatoid arthritis. Science 1991;253:325-9.
8. Bucht A, Oksenberg JR, Lindblad S, Gronberg A, Steinman L, Klareskog L: Characterization of T cell receptor ß repertoire in synovial tissue from different temporal phases of rheumatoid arthritis. Scand J Immunol 1992;35:159-165
9. Jenkins RN, Nikaein A, Zimmermann A, Meek K, Lipsky PE: T cell receptor Vß gene bias in rheumatoid arthritis. J Clin Invest 1993;92:2688-2701
10. Williams WV, Fang Q, Demarco D, VonFeldt J, Zurier RB, Weiner DB: Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium. J Clin Invest 1992;90:326-33
11. Howell MD, Diveley JP, Lundeen KA, et al: Limited T cell receptor B-chain heterogenity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis. Proc Nat Acad Sci USA 1991;88:10921-5
12. Stamenkovic I, Stegagno M, Wright KA, et al: Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci USA 1988;85:1179-1183
13. Cooper SM, Dier DL, Roessner KD, Budd RC, Nicklas JA: Diversity of rheumatoid synovial tissue T cells by T cell receptor analysis: Oligoclonal expansion in interleukin-2 responsive cells. Arthritis Rheum 1991;34:537-546.
14. Miltenburg AMM, Van Laar JJ, Daha MR, De Vries RRP, van den Elsen PJ, Breedveld FC: Dominant T cell receptor B-chain gene rearrangements indicate clonal expansion in the rheumatoid joint. Scand J Immunol 1990;31:121-5
15. Duby AD, Sinclair AK, Osborne-Lawrence SL, Zeldes W, Kan L, Fox DA: Clonal heterogeneity of synovial fluid T lymphocytes from patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1989;86:6206-10.
16. Uematsu Y, Wege H, Straus A, et al: The T cell-receptor repertoire in the synovial fluid of a patient with rheumatoid arthritis is polyclonal. Proc Natl Acad Sci USA 1991;88:8534-8.
17. Sottini A, Imberti L, Goria R, Cattaneo R, Primi D: Restricted expression of T cell receptor Vß but not Vα genes in rheumatoid arthritis. Eur J Immunol 1991;253:325-9
18. Grom AA, Thompson SD, Luyrink L, Passo M, Choi E, Glass DN: Dominant T cell receptor ß chain variable region Vß14+ clones in juvenile rheumatoid arthritis. Proc Natl Acad Sci USA 1993;90:1104-8
19. Korthauer U, Hennerkes B, Menninger H, et al: Oligoclonal T cells in rheumatoid arthritis: Identification strategy and molecular characterization of a clonal T cell receptor. Scand J Immunol 1992;36:855-63.
20. Lunardi C, Marguerie C, So AK: An altered repertoire of T cell receptor V gene expression by rheumatoid synovial fluid T lymphocytes. Clin Exp Immunol 1992;90:440-6.
21. Cooper SM, Roessner KD, Naito-Hoopes M, Howard DB, Gaur LK, Budd RC: Increased usage of Vß2 and Vß6 in rheumatoid synovial fluid T cells. Arthritis Rheum 1994;37:1627-36.
22. Pluschke G, Ricken G, Taube H, et al: Biased T cell receptor Vα region repertoire in the synovial fluid of rheumatoid arthritis patients. Eur J Immunol 1991;21:2749-54.
23. Der Simonian H, Sugita M, Glass DN, et al: Clonal Vα12.1+ T cell expansions in the peripheral blood of rheumatoid arthritis patients. J Exp Med 1993;177:1623-31
24. Bröker BM, Korthäuer U, Heppt P, et al: Biased T cell receptor V gene usage in rheumatoid arthritis: Oligoclonal expansion of T cells expressing Vα2 genes in synovial fluid but not in peripheral blood. Arthritis Rheum 1993;36:1234-43.
25. Williams WV, Kieber-Emmons T, Fang Q, et al: Conserved motifs in rheumatoid arthritis synovial tissue T cell receptor beta chains. DNA and Cell Biology 1993;12:425-34.
26. Lamour A, Jouen-Beades F, Lees O, Gilbert D, LeLoet X, Tron F: Analysis of T cell receptors in rheumatoid arthritis: The increased expression of HLA-DR antigen on circulating gamma delta + T cells is correlated with disease activity. Clin Exp Immunol 1992;89: 217-22
27. Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
28. Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
29. Steinman L: The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease. Adv Immunol 1991;49:357-79.
30. Wraith DW, McDevitt HO, Steinman L, Acha-Orbea H: T cell recognition as the target for immune intervention in autoimmune disease. Cell 1989;57:709-15.
31. Sioud M, Kjeldsen-Kragh J, Quayle AJ, et al: Immune responses to 18.6 and 30-kDa mycobacterial antigens in rheumatoid patients, and Vß usage by specific synovial T cell lines and fresh T cells. Scand J Immunol 1991;34:803-12.
32. Koopman WJ: Host factors in the pathogenesis of arthritis triggered by infectious organisms. Overview. Rheum Dis Clin North Am 1993;19:279-92.
33. Li SG, Quayle AJ, Shen Y, et al: Myobacteria and human heat shock protein-specific cytotoxic T lymphocytes in rheumatoid synovial inflammation. Arthritis Rheum 1992;35:270-81.
34. Friedman SM, Posnett DN, Tumang JR, Cole BC, Crow MK: A potential role for microbial superantigens in the pathogenesis of systemic autoimmune disease. Arthritis Rheum 1991;34:468-80.
35. Friedman SM, Crow MK, Tumang JR, et al: Characterization of human T cells reactive with the Mycoplasma arthritidis-derived superantigen (MAM): Generation of monoclonal antibody against Vß17, the T cell receptor gene product expressed by a large fraction of MAM-reactive human T cells. J Exp Med 1991;174:891-900.
36. Bhardwaj N, Hodtsev AS, Nisanian A, et al: Human T cell responses to mycoplasma arthritidis-derived superantigen. Infect Immun 1994;62:135-44
37. Marrack P, Kappler J: The staphylococcal enterotoxins and their relatives. Science 1990;248:705-11.
38. Van Eden W, Holoshitz J, Nero J, Frenkel A, Klajman A, Cohen IR: Arthritis induced by a T-lymphocyte clone that responds to mycobacterium tuberculosis and to cartilage proteoglycans. Proc Nat Acad Sci USA 1985;82:5117-20.
39. Holmdahl R, Klareskog L, Rubin K, Larssan E, Wigzell H: T lymphocytes in collagen II induced arthritis in mice: Characterization of arthritogenic collagen II - specific T cell lines and clones. Scand J Immunol 1985;22:295-306.
40. Banerjee S, Haqqi TM, Luthra HS, Stuart JM, David CS: Possible role of Vß T cell receptor genes in susceptibility to collagen-induced arthritis in mice. J Exp Med 1988;167:532-9.
41. Chiocchia G, Boissier MC, Fournier C: Therapy against murine collagen-induced arthritis with T cell receptor Vß specific antibodies. Eur J Immunol 1991;21:2899-905.
42. Yoshino S, Schlipkoter E, Kinne R, Hunig T, Emmrich F: Suppression and prevention of adjuvant arthritis in rats by a monoclonal antibody to the α/ß T cell receptor. Eur J Immunol 1990;20:2805-8.
43. Ranges GE, Sriram S, Cooper SM: Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985;162:1105-10.
44. Griffiths MM, Cole BC, Ito J, et al: T cell receptors and collagen induced arthritis in H-2r mice. Autoimmunity 1993;14:221-9
45. Moder KG, Luthra HS, Kubo R, Griffiths M, David CS: Prevention of collagen induced arthritis in mice by treatment with an antibody directed against the T cell receptor alpha beta framework. Autoimmunity 1992;11:219-24.
46. Gustafsson K, Karlsson M, Anderson L, Holmdahl R: Structures on the I-A molecule predisposing for susceptibility to type II collagen-induced autoimmune arthritis. Eur J Immunol 1990;20:2127-31.
47. Lider O, Karin N, Shinitsky M, Cohen IR: Therapeutic vaccination against adjuvant arthritis using autoimmune T cells treated with hydrostatic pressure. Proc Natl Acad Sci USA 1987;84:4577-80.
48. Mor F, Lohse AW, Karin N, Cohen IR: Clinical modeling of T cell vaccination against autoimmune disease in rats: Selection of antigen-specific T cells using a mitogen. J Clin Invest 1990;85: 1594-8.
49. Kakimoto K, Katsuki M, Hirofuji T, Iwata H, Koya T: Isolation of T cell line capable of protecting mice against collagen-induced arthritis. J Immunol 1988;140:78-83.
50. Holoshitz J, Matitian H, Cohen IR: Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria. J Clin Invest 1984;13:211-5.
51. Yoshino S, Kinne R, Hüng T, Emmrich F: The suppressive effect of an antibody to the αß cell receptor in rat adjuvant arthritis: Studies on optimal treatment protocols. Autoimmunity 1990;7:255-66.
52. Myers LK, Seyer JM, Stuart JM, Terato K, David CS, Kang AH: T cell epitopes of type II collagen that regulate murine collagen-induced arthritis. J Immunol 1993;151:500-5.
53. Osman LE, Toda M, Kanagawa O, Hood LE: Characterization of the T cell receptor repertoire causing collagen arthritis in mice. J Exp Med 1993;177:387-95.
54. Horn JT, Estridge T, Cole H, Gliszczynski V, Bendele A: Effects of various anti-T cell receptor antibodies on the development of type II collagen-induced arthritis in mice. Immunol Investig 1993;22:257-65.
55. Yoshino S, Yoshino J: Suppression of chronic antigen-induced arthritis in rats by a monoclonal antibody against the T cell receptor αß. Cellular Immunol 1992;1144:382-91.
56. Savill CM, Delves PJ, Kioussis D, et al: A minority of patients with rheumatoid arthritis show a dominant rearrangement of T cell receptor ß chain genes in synovial lymphocytes. Scand J Immunol 1987;25:629-35.
57. Keystone EC, Minden M, Klock R, et al: Structure of T cell antigen receptor ß chain genes in synovial fluid cells from patients with rheumatoid arthritis. Arthritis Rheum 1988;31:1555-7.
58. Doherty PJ, Yang SX, Laxer RM, Silverman ED, Inman R, Pan S: Evidence for clonal expansion of T cell receptor VγII+ T cells in the synovial fluid of patients with rheumatoid arthritis. J Immunol 1992;149:295-9.
59. Hylton W, Smith-Burchnell C, Pelton BK, Palmer RG, Denman AM, Malkovsky M: Polyclonal origin of rheumatoid synovial T-lymphocytes. Br J Rheumatol 1992;31:55-7.
60. Van Laar JM, Miltenburg AMM, Verdonk MJA, et al: Lack of T cell oligoclonality in enzyme-digested synovial tissue and in synovial fluid in most patients with rheumatoid arthritis. Clin Exp Immunol 1991;83:352-8.
61. Struyk L, Kurnick JT, Hawes GE, et al: T cell receptor V-gene usage in synovial fluid lymphocytes of patients with chronic arthritis. Hum Immunol 1993;37:237-51.
62. Davey M, Munkirs DD: Patterns of T cell receptor variable ß gene expression by synovial fluid and peripheral blood T cells in rheumatoid arthritis. Clin Immunol Immunopathol 1993;68:79-87.
63. Krawinkel U, Pluschke G: T cell receptor variable region repertoire in lymphocytes from rheumatoid arthritis patients. Immunobiol 1992;185:483-91.
64. Brennan FM, Allard S, Londei M, et al: Heterogeneity of T cell receptor idiotypes in rheumatoid arthritis. Clin Exp Immunol 1988;73:417-23.
65. Olive C, Gatenby PA, Serjeantson SW: Variable gene usage of T cell receptor gamma- and delta-chain transcripts expressed in synovia and peripheral blood of patients with rheumatoid arthritis. Clin Exp Immunol 1992;87:172-7.
66. Happ MP, Kiraly A, Offner H, Vandenbark AA, Heber-Katz E: The autoreactive T cell population in EAE: TCR ß chain rearrangements. J Neuroimmunol 1988;19:191-9.
67. Burns FR, Li X, Shen N, et al: Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar Vα and Vß chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J Exp Med 1989;169:27-39.
68. Urban JL, Kumar V, Kono DH, et al: Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell 1988;54:517-92.
69. Acha-Orbea H, Mitchell DJ, Timmermann L, et al: Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows special immune intervention. Cell 1988;54:263-73.
70. Ben-Nun A, Wekerle H, Cohen IR: Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981;292:60-1.
71. Sriram S, Steinman L: Anti I-A antibody suppresses active encephalomyelitis: Treatment model for diseases linked to IR genes. J Exp Med 1983;158:1362-7.
72. Wraith DC, Smiler DE, Mitchell DJ, Steinman L, McDevitt HO: Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunity. Cell 1989;59:247-55.
73. Gaur A, Wiers B, Liu A, Rothbard J, Fathman GC: Amelioration of autoimmune encephalitis by myelin basic protein synthetic peptide-induced anergy. Science 1992;258:1491-4.
74. Sharma SD, Nag B, Su X, et al: Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Nat Acad Sci USA 1991;88:11465-9.
75. Waldor MK, Sriram S, Hardy R, et al: Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T cell subset marker. Science 1985;227:415-7.
76. Brostoff SW, Mason DM: Experimental allergic encephalomyelitis: Successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J Immunol 1984;133:1938-42.
77. Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW: Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 1989;246:668-70.
78. Vandenbark AA, Hashim G, Offner H: Immunization with a synthetic T cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989;3 41:541-4.
79. Offner H, Hashim G, Vandenbark AA: T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 1991;251:430-2.
80. Whitham RH, Kotzin BL, Buenafe AC, et al: Treatment of relapsing experimental autoimmune encephalomyelitis with T cell receptor peptides. J Neuroscience Res 1993;35:115-128.
81. Offner H, Jones R, Celnik B, Vandenbark AA: Lymphocyte vaccination against experimental autoimmune encephalomyelitis: Evaluation of vaccination protocols. J Neuroimmunol 1989;21:13-22.
82. Lee SJ, Wucherpfenning KW, Brod SA, Benjamin D, Weiner HL, Hafler DA: Common T cell receptor Vß usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Ann Neurol 1991;29:33-40.
83. Birnbaum G, Van Ness B: Quantitation of T cell receptor Vß chain expression on lymphocytes from blood, brain, and spinal fluid in patients with multiple sclerosis and other neurologic diseases. Ann Neurol 1992;32:24-30.
84. Richert JR, Robinson ED, Johnson AH, et al: Heterogeneity of the T cell receptor ß gene rearrangements generated in myelin basic protein-specific T cell clones isolated from a patient with multiple sclerosis. Ann Neurol 1991;29:299-306.
85. Oksenberg JR, Panzara MA, Begovich AB, et al: Selection for T cell receptor Vß-Dß-Jß gene rearrangements with specificity for myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 1993;362:68-70.
86. Oksenberg JR, Stuart S, Begovich AB, et al: Limited heterogeneity of rearranged T cell receptor V transcripts in brains of multiple sclerosis patients. Nature 1990;345:344-6.
87. Kotzin BL, Karuturi S, Chou YK, et al: Preferential T cell receptor ß-chain variable gene use in myelin basic protein-reactive T cell clones from patients with multiple sclerosis. Proc Nat Acad Sci USA 1991;88:9161-5.
88. Allegretta M, Albertini RJ, Howell MD, et al: Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis. J Clin Invest 1994;94:105-9.
89. Bourdette DN, Whitham RH, Chou YK, et al: Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vß5.2 and Vß 6.1 CDR 2 peptides. J Immunol1994;152:2510-9.
90. Chou YK, Morrison WJ, Weinberg AD, et al: Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of Vß 5.2 and Vß 6.1 CDR 2 peptides. J Immunol1994;1152:2520-9.
91. Kumar V, Sercarz EE. The involvement of T cell receptor peptide-specific regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease. J Exp Med1995;178:909-16
92. Gaur A, Haspal R, Mayer JP, Fathman CG: Requirement for CD8+ cells in T cell receptor peptide-induced clonal unresponsiveness. Science 1993;259:91-4.
93. Kuhröber A, Schirmbeck R, Reimann J: Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL. Eur J Immunol 1994;24:1172-80.
94. Desquenne-Clark L, Esch TR, Otvos L Jr, Heber-Katz E: T cell receptor peptide immunization leads to enhanced and chronic experimental encephalomyelitis. Proc Nat Acad Sci 1991;88:7219-23.
95. Kahn CR, McIntosh KR, Drachman DB: T cell vaccination in experimental myasthenia gravis: A double-edged sword. J Autoimmunity 1990;3:659-69.
96. Maeda T, Saikawa I, Hotokebuchi T, et al: Exacerbation of established collagen-induced arthritis in mice treated with an anti-T cell receptor antibody. Arthritis Rheum 1994;37:406-13.